

Phenolic profile and antioxidant activity of Maritime pine (*Pinus pinaster* subsp. *Atlantica*) bark extract during simulated gastrointestinal tract digestion

Tiago Afonso^{1,2}, Márcio Carrocho^{1,3}, Sandrina Heleno^{1,3}, Tiane C. Finimundy^{1,3}, Manuela Vaz Velho⁴, Manuela Pintado², Lillian Barros^{1,3}

¹Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal

²Centre for Biotechnology and Fine Chemistry, Universidade Católica Portuguesa, Porto, Portugal

³Laboratório Associado para a Sustentabilidade e Tecnologia em Regiões de Montanha (SusTEC), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal

⁴Centro de Investigação em Sistemas Agroalimentares e Sustentabilidade (CISAS), Instituto Politécnico de Viana do Castelo, R. Escola Industrial e Comercial Nun'Álvares, 4900-347 Viana do Castelo, Portugal

*lillian@ipb.pt

Maritime pine (*Pinus pinaster* subsp. *atlantica*) is native to the western Mediterranean basin, especially southwestern Europe which includes the Iberian Peninsula. It has economic importance due to the use of its wood in the furniture, construction and paper industries. Bark and other parts of the plant are by-products with a variety of potential applications. This is due to the presence of secondary metabolites, especially phenolic compounds and terpenes [1]. In this work, an extract rich in phytochemicals, obtained from Maritime pine bark was selected to be evaluated as an additive to meat cured products. The gastrointestinal environment can modify the compounds present in the extract and lead to new combinations with different bioactivities. Thus, two concentrations of pure extract were submitted to a simulated gastrointestinal tract digestion.



Conditions tested:

Pure extract:

- **3 mg** extract – Equivalent to one product dose.
- **27 mg** extract – Equivalent to a whole product.

Infogest Protocol [2]:

Oral Phase:

Mix 1:1 with Simulated Salivary Fluid (SSF)
2 min at 37 °C pH 7, 200 rpm

Gastric Phase:

Mix 1:1 with Simulated Gastric Fluid (SGF)
pepsin (2000 U/mL) and gastric lipase (60 U/mL)
2 h at 37 °C, pH 3, 130 rpm

Intestinal Phase:

Mix 1:1 with Simulated Intestinal Fluid (SIF)
Pancreatin (100 U/mL) and bile salts (10 nM)
2 h at 37 °C, pH 3, 45 rpm

At the end of each phase, samples were collected and characterized for their phenolic profile and antioxidant activity.





Figure 1. Antioxidant activity of Maritime pine bark extract during simulated gastrointestinal digestion through ABTS and DPPH methods.

Table 1. Phenolic profile obtained through HPLC-DAD-ESI/MS of the 3 and 27 mg of Maritime pine bark extract in the oral and intestinal phases.

Peak	Rt	λmax	[M-H] ⁻ m/z	3mg Extract		Tentative Identification	Oral µg/mL Average ± SD	Intestinal µg/mL Average ± SD
				M ^s	M ^s			
1	4.24	281	577	559(47),467(18),451(100),425(65),407(49),289(55)		B-type procyanidin dimer	1.269±0.001	-
2	4.86	280	289	245(100),205(35),179(22),125(5)		(+)-Catechin	3.722±0.065	18.63±0.43
3	5.44	281	865	801(31),789(47),779(100),720(65),695(41),577(64),575(35)		B-type procyanidin trimer	2.52±0.04	-
4	5.94	281	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	0.982±0.005	-
5	6.36	280	575	449(50),423(100),407(30),289(5),287(20),285(10)		A-type procyanidin dimer	1.18±0.004	-
6	6.69	280	865	801(31),789(47),779(100),720(65),695(41),577(64),575(35)		B-type procyanidin trimer	1.873±0.062	-
7	6.87	280	289	245(100),205(35),179(22),125(5)		(-)-Epicatechin	1.194±0.002	-
8	7.47	280	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	1.714±0.056	-
9	7.93	280	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	1.331±0.003	-
10	10.51	280	1151	981(100),863(89),575(36),289(18)		A-type procyanidin tetramers	1.911±0.062	-
11	11.54	282±h322	465	303(100),285(20)		Taxifolin-7-O-hexoside	0.986±0.01	-
12	12.52	280	575	449(50),423(100),407(30),289(5),287(20),285(10)		A-type procyanidin dimer	2.022±0.074	-
13	14.41	281	1151	1009(100),863(89),575(36),289(18)		A-type procyanidin tetramers	2.149±0.032	-
14	14.75	281	1151	1009(100),863(89),575(36),289(18)		A-type procyanidin tetramers	18.714±0.462	-
15	15.06	280	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	1.952±0.046	-
Total Phenolic Compounds							43.52±0.63	18.63±0.43

Peak	Rt	λmax	[M-H] ⁻ m/z	27mg Extract		Tentative Identification	Oral µg/mL Average ± SD	Intestinal µg/mL Average ± SD
				M ^s	M ^s			
1	4.24	281	577	559(47),467(18),451(100),425(65),407(49),289(55)		B-type procyanidin dimer	5.31±0.04	-
2	4.86	280	289	245(100),205(35),179(22),125(5)		(+)-Catechin	17.25±0.36	10.98±0.41
3	5.44	281	865	801(31),789(47),779(100),720(65),695(41),577(64),575(35)		B-type procyanidin trimer	12.58±0.28	-
4	5.94	281	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	2.48±0.05	-
5	6.36	280	575	449(50),423(100),407(30),289(5),287(20),285(10)		A-type procyanidin dimer	3.1±0.04	-
6	6.69	280	865	801(31),789(47),779(100),720(65),695(41),577(64),575(35)		B-type procyanidin trimer	9.99±0.54	5.23±0.06
7	6.87	280	289	245(100),205(35),179(22),125(5)		(-)-Epicatechin	2.15±0.04	-
8	7.47	280	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	3.44±0.04	-
9	7.93	280	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	4.8±0.03	-
10	10.51	280	1151	981(100),863(89),575(36),289(18)		A-type procyanidin tetramers	10.11±0.41	10.87±0.58
11	11.54	282±h322	465	303(100),285(20)		Taxifolin-7-O-hexoside	3.33±0.16	11.09±0.47
12	12.52	280	575	449(50),423(100),407(30),289(5),287(20),285(10)		A-type procyanidin dimer	13.46±0.62	-
13	14.41	281	1151	1009(100),863(89),575(36),289(18)		A-type procyanidin tetramers	9.17±0.41	12.58±0.39
14	14.75	281	1151	1009(100),863(89),575(36),289(18)		A-type procyanidin tetramers	120.82±6.43	-
15	15.06	280	1153	865(27),577(56),289(49)		B-type procyanidin tetramers	10.35±0.37	-
Total Phenolic Compounds							228.35±9.83	50.74±1.92

Acknowledgements

The authors are grateful to FCT (Portugal) for financial support through national funds FCT/MCTES (PIDDAC) to CIMO (UIDB/00690/2020 and UIDP/00690/2020) and SusTEC (LA/P/0007/2020); M. Carrocho (CEEC-IND/00831/2018), L. Barros and S. Heleno thank FCT for their Individual and Institutional Employment Program-Contracts. The European Regional Development Fund (ERDF) financed this work through the Regional Operation Program North 2020, within the scope of the R&D Enterprise Copromotion project PICAR (NORTE-01-0247-FEDER-069584).

References

- [1] J. I. Alonso-Esteban, M. Carrocho, D. Barros, M. Vaz Velho, S. Heleno, L. Barros, Rev. Environ. Sci. Biotechnol., 21 (2022) 583.
[2] A. Brodkorb, L. Egger, M. Alving, P. Alvito, R. Assunção, S. Balance, T. Bohn et al. Nat. Protoc., 14 (2019) 991-1014.